Suchergebnisse - (Subject:"Adalimumab")

PubPharm (12.453)

41

Impact of filgotinib on pain control in the phase 3 FINCH studies

enthalten in: RMD open | 2024

von Taylor, P. | Kavanaugh, A. | Nash, P. | +10

ErratumIn: RMD Open. 2024 Apr 4;10(2):. - PMID 38580354

42

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era : A Narrative Review

enthalten in: Advances in therapy | 2024

von Allegretti, J. | Brady, J. | Wicker, A. | +2

43

Adalimumab as a cause of kidney injury in patients with Crohn's disease

enthalten in: Pediatric nephrology (Berlin, Germany) | 2024

von Skoczyński, K. | Koziej, J. | Szymańska, S. | +3

44

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies : A Quantitative Pharmacology Framework

enthalten in: The AAPS journal | 2024

von Williams, J. | Liao, K. | Yin, D. | +1

45

Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases : an observational study on the French National Health Data System

enthalten in: RMD open | 2024

von Jourdain, H. | Hoisnard, L. | Sbidian, E. | +1

46

Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors : Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance

enthalten in: Clinical drug investigation | 2024

von Colina, M. | Khodeir, M. | Rimondini, R. | +4

47

Tofacitinib for Refractory Uveitis and Scleritis in Children : A Case Series

enthalten in: Ocular immunology and inflammation | 2024

von Dutta Majumder, P. | Abraham, S. | Sudharshan, S. | +2

48

Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?

enthalten in: Clinical rheumatology | 2024

von Teh, K. | Das, L. | Book, Y. | +3

49

Biosimilars in IBD : What Every Clinician Needs to Know

enthalten in: Current gastroenterology reports | 2024

von Angyal, A. | Bhat, S.

50

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

enthalten in: Rheumatology and therapy | 2024

von Jin, R. | Kruppert, S. | Scholz, F. | +6